- Eclipsebio’s eVERSE™ provides access to AI-ready data from their comprehensive portfolio of next-generation sequencing technologies, including measurements of RNA secondary structure, protein translation, and regulatory regions.
- Eclipsebio’s partners can improve AI-powered drug discovery with reproducible and high-quality data capturing key determinants of siRNA, ASO, and mRNA-based therapy efficacy.
SAN DIEGO, June 10, 2025 — Eclipse Bioinnovations, Inc. (Eclipsebio), the leading partner for RNA-based and RNA-targeting therapeutic development, today announced the launch of its eVERSE™ portfolio of AI-ready datasets. eVERSE is a first-in-class collection of datasets generated from all key aspects of RNA biology that inform therapeutic development from target discovery to drug design. Eclipsebio will reveal eVERSE at the Computational RNA Design & Delivery Summit on June 25, 2025.
“Artificial intelligence and machine learning are the future of developing life-saving therapies, yet a major challenge for their use is obtaining high-quality and reproducible data,” said Eclipsebio Co-Founder and CEO Peter Chu, Ph.D. “eVERSE is a one-of-a-kind portfolio of training datasets generated directly by our team of RNA biologists at Eclipsebio. These validated datasets provide the direct measurements needed to develop safe and effective small oligonucleotide, small molecule and RNA-based therapies.”
eVERSE provides actionable, multidimensional training data from Eclipsebio’s full suite of next-generation sequencing technologies. These include measurements of RNA secondary structure, protein translation, RNA regulatory regions, and base modifications. As the exclusive provider of these assays in the United States, Eclipsebio’s eVERSE provides partners with training data that is not available anywhere else. In addition to ready-to-download datasets, partners can also obtain custom datasets from specific cell lines, tissues, or disease conditions.
About Eclipsebio
Eclipsebio is a private biotechnology company headquartered in San Diego developing first-in-class technologies, analyses, and platforms for the development of tomorrow’s RNA-based and RNA-targeting therapies. With the company’s extensive experience in supporting early-stage basic research to evaluating preclinical therapies, they provide unparalleled support for obtaining deep insights into RNA and therapeutic biology. The company offers its solutions as end-to-end partnerships, including custom assay development, for biopharma and as a la carte services for academics. For more information about Eclipsebio, visit www.eclipsebio.com.
Contacts
For Partners: everse@eclipsebio.com
For Media: press@eclipsebio.com
Latest news
Eclipsebio expands its RNA characterization capabilities with multi-attribute nanopore-based sequencing assay eSTRAND RNA QC™
eSTRAND RNA QC uses direct RNA sequencing to provide multiple critical quality attributes in a single run without requiring reverse transcription or translation.
Wacker Biotech and Eclipsebio Announce Strategic Collaboration to Advance RNA Medicine Development and Production
The collaboration will combine Wacker Biotech's large-scale, GMP-compliant manufacturing with Eclipsebio's AI-driven RNA design and sequencing-based characterization for best-in-class end-to-end RNA therapeutic development support.
RNA Delivery Prato 2026
Eclipsebio is proud to sponsor the 2026 RNA Delivery Prato meeting to discuss recent discoveries and challenges in RNA delivery.
Eclipsebio Expands eCOMPASS™ Platform with eSENSE Break™ to Map RNA Fragmentation at Nucleotide Resolution
Eclipsebio's eSENSE Break uses sequencing-based analytics to map RNA fragmentation and circular RNA nicking sites at single-nucleotide resolution.